These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30703438)

  • 21. Biologics and severe asthma in children.
    Saxena S; Rosas-Salazar C; Fitzpatrick A; Bacharier LB
    Curr Opin Allergy Clin Immunol; 2023 Apr; 23(2):111-118. PubMed ID: 36730217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 24. Biologics for severe asthma-Which, when and why?
    Shah PA; Brightling C
    Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children?
    Gaberino CL; Bacharier LB; Jackson DJ
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2673-2682. PubMed ID: 37517797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
    Santus P; Saad M; Damiani G; Patella V; Radovanovic D
    Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.
    Pilkington AW; Buragamadagu B; Johnston RA
    Curr Allergy Asthma Rep; 2024 Jul; 24(7):381-393. PubMed ID: 38878250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC; Mauskopf J; Borker R
    Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
    Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
    Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of asthma therapy: a comprehensive review.
    Domínguez-Ortega J; Phillips-Anglés E; Barranco P; Quirce S
    J Asthma; 2015; 52(6):529-37. PubMed ID: 25539023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
    Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.
    Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
    Pharmacoeconomics; 2018 Oct; 36(10):1165-1200. PubMed ID: 29869050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine.
    Mustafa SS; Patrawala S; Khurana S
    Curr Opin Pulm Med; 2022 May; 28(3):266-273. PubMed ID: 35131991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
    Stawowczyk E; Kawalec P
    Pharmacoeconomics; 2018 Apr; 36(4):419-434. PubMed ID: 29260508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors to Consider in Prescribing Asthma Biologic Therapies to Children.
    Anderson WC; Banzon TM; Chawes B; Papadopoulos NG; Phipatanakul W; Szefler SJ
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):693-701. PubMed ID: 36646381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
    Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
    Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
    Dudiak GJ; Popyack J; Grimm C; Tyson S; Solic J; Ishmael FT
    Allergy Asthma Proc; 2021 Jan; 42(1):65-71. PubMed ID: 33404389
    [No Abstract]   [Full Text] [Related]  

  • 40. Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use.
    Denton E; Lee J; Tay T; Radhakrishna N; Hore-Lacy F; Mackay A; Hoy R; Dabscheck E; O'Hehir RE; Hew M
    J Allergy Clin Immunol Pract; 2020 May; 8(5):1616-1624. PubMed ID: 31954193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.